Investors & Media

Jun 4, 2020 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Jun 4, 2020 / Jun 4, 2020 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

5/28/20

BELLUS Health to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
LAVAL, Quebec --(BUSINESS WIRE)--May 28, 2020-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced...
Read More
5/14/20

BELLUS Health Reports First Quarter 2020 Financial Results and Business Highlights, and Provides Updates on BLU-5937
LAVAL, Quebec --(BUSINESS WIRE)--May 14, 2020-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported...
Read More
5/13/20

BELLUS Health Convenes Virtual KOL Meeting to Discuss the State of Chronic Cough Treatment and the BLU-5937 Program
LAVAL, Quebec --(BUSINESS WIRE)--May 13, 2020-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (" BELLUS Health " or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today...
Read More